Here you will find the very latest program information for the Cell & Gene Therapy Forum 2010. It's not too late for your input, please complete a Shape Your Event form, or contact david@phacilitate.co.uk with any suggestions.
|
|
|
|
Day 1 - Monday 25th January 2010
|
|
Morning plenary session
How will cell therapies, gene therapies and tissue-engineered products fit in to a reforming healthcare picture? Examining the commercialization strategies of companies in pivotal trials
- What degree of benefit will they need to deliver to secure reimbursement?
|
|
Followed by your choice of three highly interactive parallel sessions:
|
|
Focus session 1
An in-depth examination of autologous and allogeneic cell therapy business models: What are the keys to achieving commercial viability?
|
Focus session 2
Gene therapy clinical update: Analyzing recent clinical success stories in key therapeutic areas to inform your trial design strategy
|
Workshop*
Providing practical insights into how to build a commercially focused cell/gene therapy or tissue engineered product company from the ground up
•What are the key business challenges you will face at each stage of R&D, and how can you prepare to meet them?
|
|
Followed by afternoon plenary session
|
|
What traditional and alternative funding options are now open to academics and companies seeking to translate preclinical cell/gene therapy and tissue engineered product candidates to Phase IIa and beyond?
|
|
| Day 2 - Tuesday 26th January 2010 |
|
Morning plenary session
How will big pharma drive the continuing maturation of the cell and gene therapy sector?
|
|
Followed by your choice of three highly interactive parallel sessions:
|
|
Focus session 1
Driving the product characterization and optimization of cell & gene therapies through scale-up
|
OR | Focus session 2
What breakthroughs are being achieved in defining the Mechanism of Action (MoA) of cell therapies as they advance towards and through the clinic?
|
OR | Workshop*
Regulatory 'surgeries'
|
|
Followed by afternoon plenary session
|
|
Afternoon plenary session
How are regulatory frameworks and guidelines for cell/gene therapies and tissue-engineered products continuing to evolve on a global basis?
• Delivering the latest updates from the US, Europe, Asia and Oceania
|
|
| Day 3 - Wednesday 27th January 2010 |
|
Morning plenary session
Picking the winners: Assessing the prospects of - and progress with - emerging technologies
• What are the keys to accessing Government funding in order to help realize their potential?
|
|
Followed by your choice of three parallel sessions:
|
|
Focus session 1
Delivering strategic solutions to the key cost control issues and risk management conundrums with cell and gene therapy products
• How to minimize Cost of Goods (CoG)?
• Build or buy?
• How to efficiently source both capacity and materials?
|
Focus session 2
Stem cell therapy clinical strategy and data update
• How are leading candidates performing in the clinic?
• Addressing key fundamental questions regarding the sourcing and delivery of stem cells
|
OR | Workshop*
Overcoming the remaining challenges with viral and non-viral delivery platforms for gene and RNAi therapies
|
